Biotech firm Quantum-Si Q2 revenue of $591,000
Overview
Quantum-Si Q2 2025 revenue at $591,000, impacted by NIH funding challenges
Co raises $50 mln in capital, extending cash runway to Q2 2028
Product development on track with v4 Sequencing Kit launch in Q3 2025
Outlook
Company expects Q3 2025 launch of v4 Sequencing Kit
Quantum-Si plans Q4 2025 launch of v3 Library Preparation Kit
Company aims for successful protein sequencing on Proteus by end of 2025
Quantum-Si sees sufficient capital to operate into Q2 2028
Result Drivers
NIH FUNDING CHALLENGES - Co reports NIH funding issues slowed capital sales, impacting Q2 revenue
INSTRUMENT OPTIONS - Expanded instrument acquisition options launched to drive user base growth and consumable revenue
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| $591,000 |
|
Q2 EPS |
| -$0.16 |
|
Q2 Net Income |
| -$28.84 mln |
|
Q2 Operating Expenses |
| $30.47 mln |
|
Q2 Operating Income |
| -$30.12 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Quantum-Si Inc is $3.50, about 58.9% above its August 4 closing price of $1.44
Press Release: ID:nBw6lBLR4a
